Antipsychotic drugs in Huntington's disease

被引：22

作者：

Unti, E. ^{[1
]}

Mazzucchi, S. ^{[1
]}

Palermo, G. ^{[1
]}

Bonuccelli, U. ^{[1
]}

Ceravolo, R. ^{[1
]}

机构：

[1] Univ Pisa, Dept Clin & Expt Med, Neurol Unit, Pisa, Italy

来源：

EXPERT REVIEW OF NEUROTHERAPEUTICS | 2017年 / 17卷 / 03期

关键词：

Huntington's disease; antipsychotic drugs; extrapiramidal side effects; aggressiveness; involuntary movements; DOUBLE-BLIND TRIAL; 1ST CASE-REPORT; PHARMACOLOGICAL-TREATMENT; MOVEMENT-DISORDERS; STRIATAL NEURONS; CHOREA; RISPERIDONE; ARIPIPRAZOLE; TETRABENAZINE; OLANZAPINE;

D O I：

10.1080/14737175.2016.1226134

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Introduction: The aim of this review is to overview the pharmacological features of neuroleptics experienced in the treatment of Huntington's disease (HD) symptoms. Despite a large number of case reports, randomized controlled trials (RCT) and drug comparison studies are lacking.Areas covered: After evaluating current guidelines and clinical unmet needs we searched PubMed for the term Huntington's disease' cross referenced with the terms Antipsychotic drugs' Neuroleptic drugs' and single drug specific names.Expert commentary: In clinical practice antipsychotics represent the first choice in the management of chorea in the presence of psychiatric symptoms, when poor compliance is suspected or when there is an increased risk of adverse events due to tetrabenazine. Antipsychotics are considered valid strategies, with the second generation preferred to reduce extrapyramidal adverse events, however they may cause more metabolic side effects. In the future dopamine stabilizers', such as pridopidine, could replace antipsychotics modulating dopamine transmission.

引用

页码：227 / 237

页数：11

共 83 条

[1] Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease [J].

Alpay, M ;

Koroshetz, WJ .

PSYCHOSOMATICS, 2006, 47 (01) :70-72

[2] Pridopidine for Huntington disease falls short of primary efficacy end point in phase III trial [J].

Nature Reviews Neurology, 2012, 8 (1) :4-4

[3] Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease Report of the Guideline Development Subcommittee of the American Academy of Neurology [J].

Armstrong, Melissa J. ;

Miyasaki, Janis M. .

NEUROLOGY, 2012, 79 (06) :597-603

[4] SERUM HALOPERIDOL CONCENTRATION AND CHOREIFORM MOVEMENTS IN HUNTINGTONS-DISEASE [J].

BARR, AN ;

FISCHER, JH ;

KOLLER, WC ;

SPUNT, AL ;

SINGHAL, A .

NEUROLOGY, 1988, 38 (01) :84-88

[5] Huntington disease [J].

Bates, Gillian P. ;

Dorsey, Ray ;

Gusella, James F. ;

Hayden, Michael R. ;

Kay, Chris ;

Leavitt, Blair R. ;

Nance, Martha ;

Ross, Christopher A. ;

Scahill, Rachael I. ;

Wetzel, Ronald ;

Wild, Edward J. ;

Tabrizi, Sarah J. .

NATURE REVIEWS DISEASE PRIMERS, 2015, 1

[6] Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II [J].

Benchoua, Alexandra ;

Trioulier, Yael ;

Diguet, Elsa ;

Malgorn, Carole ;

Gaillard, Marie-Claude ;

Dufour, Noelle ;

Elalouf, Jean-Marc ;

Krajewski, Stan ;

Hantraye, Philippe ;

Deglon, Nicole ;

Brouillet, Emmanuel .

HUMAN MOLECULAR GENETICS, 2008, 17 (10) :1446-1456

[7] Pharmacological management of Huntington's disease: An evidence-based review [J].

Bonelli, Raphael M. ;

Wenning, Gregor K. .

CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (21) :2701-2720

[8] Ziprasidone in Huntington's disease: the first case reports [J].

Bonelli, RM ;

Mayr, BM ;

Niederwieser, G ;

Reisecker, F ;

Kapfhammer, HP .

JOURNAL OF PSYCHOPHARMACOLOGY, 2003, 17 (04) :459-460

[9] Quetiapine in Huntington's disease: a first case report [J].

Bonelli, RM ;

Niederwieser, G .

JOURNAL OF NEUROLOGY, 2002, 249 (08) :1114-1115

[10] Olanzapine for Huntington's disease: An open label study [J].

Bonelli, RM ;

Mahnert, FA ;

Niederwieser, G .

CLINICAL NEUROPHARMACOLOGY, 2002, 25 (05) :263-265

← 1 2 3 4 5 6 7 8 9 →